Understand the source comparison
Corticosteroids vs anti-inflammatory peptides
Dexamethasone and triamcinolone mechanisms: Broad immunosuppression through glucocorticoid receptors. Suppress multiple inflammatory pathways simultaneously. Very effective for retinal inflammation (uveitis, macular edema) but significant side effects (catarac
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Dexamethasone and triamcinolone mechanisms: Broad immunosuppression through glucocorticoid receptors. Suppress multiple inflammatory pathways simultaneously. Very effective for retinal inflammation (uveitis, macular edema) but significant side effects (cataract formation, pressure elevation, infection risk). Typically intravitreal implants or injections for sustained release.
- Peptide anti-inflammatory mechanisms: BPC-157, GHK-Cu, Thymosin Beta-4 reduce inflammation through specific pathway modulation. More targeted than steroids with fewer systemic side effects. However, less potent than corticosteroids for severe inflammation. Better suited for chronic low-grade inflammation (AMD, diabetic retinopathy) versus acute severe inflammation requiring steroids.
- Risk-benefit considerations: Steroids extremely effective but carry significant risks justifying use only when necessary. Peptides potentially providing maintenance anti-inflammatory effects between steroid treatments or preventing need for steroids in milder cases. Not equivalent potency but better safety profile for long-term use. Understanding peptide safety helps appropriate protocol development.